MIEF2 and atherosclerosis: The therapeutic efficacy of silencing MiD49/51 or augmenting miR-107 was determined by injecting the tail vein of mice early in the course of atherosclerosis with sh-RNA targeting MiD49/51 or a miR-107 mimic.